Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | EIF4E | P06730 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | BCL2 | P10415 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781132 | 0.91 | CLK1 (0.48) | KMT2ACLK1MKNK1MKNK2CYP3A4 | |
| SCHEMBL19781151 | 0.91 | CLK1 (0.48) | KMT2ACLK1MKNK1MKNK2CYP3A4 | |
| SCHEMBL19781508 | 0.90 | PARP10 (0.55) | CLK1MKNK1MKNK2CYP3A4EIF4E | |
| SCHEMBL19781539 | 0.89 | CLK1 (0.47) | CLK1MKNK1MKNK2CYP3A4FYN | |
| SCHEMBL19781805 | 0.89 | CLK1 (0.46) | KMT2ACLK1MKNK1MKNK2CYP3A4 | |
| SCHEMBL19781265 | 0.86 | CLK1 (0.46) | CLK1MKNK1MKNK2CYP3A4EIF4E | |
| SCHEMBL19781776 | 0.85 | FYN (0.54) | CLK1MKNK1MKNK2FYN | |
| SCHEMBL24460204 | 0.83 | FYN (0.54) | CLK1MKNK1MKNK2MCL1BCL2 | |
| SCHEMBL19781168 | 0.83 | SCN5A (0.50) | CLK1MKNK1MKNK2CYP3A4FYN | |
| SCHEMBL24460223 | 0.83 | BCL2 (0.44) | CLK1MKNK1MKNK2CYP3A4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | C9, C1S, ZC3HAV1 | KMT2A 1651/4885RXRA 1774/4885RXRB 2329/4885 |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | KMT2A 2960/4885RXRA 3346/4885RXRB 3685/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | KMT2A 1493/4885RXRA 1420/4885RXRB 2038/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | KMT2A 1493/4885RXRA 1420/4885RXRB 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.